The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers
GH Kamimori, CS Karyekar, R Otterstetter… - International journal of …, 2002 - Elsevier
Objective:The purpose of this study was to evaluate the rate of absorption and relative
bioavailability of caffeine from a Stay Alert® chewing gum and capsule formulation. Methods: This …
bioavailability of caffeine from a Stay Alert® chewing gum and capsule formulation. Methods: This …
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 …
Objectives To evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX)
and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA)…
and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA)…
Characterization of hepatic cytochrome p4503A activity in patients with end‐stage renal disease
…, PD Light, L Stackiewicz, CS Karyekar… - Clinical …, 2003 - Wiley Online Library
Background The cytochrome P450 (CYP) oxidative enzyme system, located primarily in the
liver and small intestine, is responsible for metabolism and detoxification of numerous …
liver and small intestine, is responsible for metabolism and detoxification of numerous …
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER …
…, B Zhou, K Sweet, M Shawi, CS Karyekar… - The Lancet …, 2021 - thelancet.com
Background Guselkumab was efficacious in reducing signs and symptoms of psoriatic arthritis
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two …
…, SD Chakravarty, S Kafka, CS Karyekar… - RMD open, 2020 - rmdopen.bmj.com
Background The interleukin-12/23p40-subunit-inhibitor ustekinumab significantly improved
spondylitis-related symptoms through Week 24 in psoriatic arthritis (PsA) patients with …
spondylitis-related symptoms through Week 24 in psoriatic arthritis (PsA) patients with …
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
…, A Parackal, CS Karyekar, S Nair… - …, 2021 - academic.oup.com
Objective The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic
arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but …
arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but …
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year …
…, P Bergmans, M Neuhold, CS Karyekar… - Annals of the …, 2022 - ard.bmj.com
Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit
antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to …
antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to …
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III …
…, B Zhou, Y Zhuang, M Shawi, CS Karyekar… - RMD open, 2021 - rmdopen.bmj.com
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort …
…, N Ohkubo, Y Tanaka, DY Yu, CS Karyekar… - The Lancet …, 2022 - thelancet.com
Background Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have
been validated to protect against organ damage and to improve quality of life. We aimed to …
been validated to protect against organ damage and to improve quality of life. We aimed to …
Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups
…, K Lheritier, K Leon, CS Karyekar… - Clinical and …, 2018 - usiena-air.unisi.it
OBJECTIVES: To describe the efficacy, safety, and exposure-response relationship of
canakinumab in a subgroup of patients with systemic juvenile idiopathic arthritis (SJIA) aged≥ 16 …
canakinumab in a subgroup of patients with systemic juvenile idiopathic arthritis (SJIA) aged≥ 16 …